PMID- 17264950
OWN - NLM
STAT- MEDLINE
DCOM- 20070323
LR  - 20161124
IS  - 0340-6245 (Print)
IS  - 0340-6245 (Linking)
VI  - 97
IP  - 2
DP  - 2007 Feb
TI  - Platelet activation by collagen is increased in retinal vein occlusion.
PG  - 218-27
AB  - Retinal vein occlusion (RVO) is the most common retinal vascular disorder second 
      to diabetic retinopathy. The main risk factors in patients with RVO are 
      hypertension, diabetes, hyperlipidemia, increased blood viscosity and glaucoma. 
      The pathogenesis of RVO has not yet been clarified. In these events platelets 
      could play a very important role. In the present study the platelet response to 
      collagen was deeply investigated. Experiments were carried out on a selected 
      group of RVO patients, which were compared to a group of healthy subjects matched 
      for age, sex, clinical and metabolic characteristics. In resting and activated 
      platelets of both groups of subjects p72syk phosphorylation, phospholipase 
      Cgamma2 phosphorylation, protein kinase C activation, intra-cellular calcium 
      levels and nitric oxide formation were measured. Results show that platelets of 
      patients were more responsive to collagen or ADP than healthy subjects and that 
      the response was significantly different (p < 0.0005) at low concentrations of 
      these agonists. In platelets of patients stimulated with collagen increased 
      phosphorylation of p72syk and phospholipase Cgamma2 was found. Also protein 
      kinase C was more activated in patients. In addition intracellular calcium rise 
      induced by collagen was significantly higher in patients than in healthy 
      subjects. RVO patients showed a lower basal level of nitric oxide both in resting 
      and stimulated platelets compared to healthy subjects. Altogether these results 
      suggest that the platelet hyperaggregability described in patients might be an 
      important factor in the development of RVO contributing to the thrombogenic 
      effects.
FAU - Leoncini, Giuliana
AU  - Leoncini G
AD  - Department of Experimental Medicine, Biochemistry section, University of Genova, 
      Viale Benedetto XV 1, I-16132 Genova, Italy. leoncini@unige.it
FAU - Bruzzese, Debora
AU  - Bruzzese D
FAU - Signorello, Maria Grazia
AU  - Signorello MG
FAU - Armani, Ugo
AU  - Armani U
FAU - Piana, Antonietta
AU  - Piana A
FAU - Ghiglione, Davidina
AU  - Ghiglione D
FAU - Camicione, Paola
AU  - Camicione P
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Germany
TA  - Thromb Haemost
JT  - Thrombosis and haemostasis
JID - 7608063
RN  - 0 (Intracellular Signaling Peptides and Proteins)
RN  - 0 (Platelet Aggregation Inhibitors)
RN  - 31C4KY9ESH (Nitric Oxide)
RN  - 61D2G4IYVH (Adenosine Diphosphate)
RN  - 9007-34-5 (Collagen)
RN  - EC 2.7.10.1 (Protein-Tyrosine Kinases)
RN  - EC 2.7.10.2 (SYK protein, human)
RN  - EC 2.7.10.2 (Syk Kinase)
RN  - EC 2.7.11.13 (Protein Kinase C)
RN  - EC 3.1.4.3 (Phospholipase C gamma)
RN  - SY7Q814VUP (Calcium)
SB  - IM
MH  - Adenosine Diphosphate
MH  - Aged
MH  - Blood Platelets/*drug effects/metabolism
MH  - Calcium/metabolism
MH  - Case-Control Studies
MH  - Collagen/*pharmacology
MH  - Dose-Response Relationship, Drug
MH  - Enzyme Activation/drug effects
MH  - Female
MH  - Humans
MH  - Intracellular Signaling Peptides and Proteins/metabolism
MH  - Male
MH  - Middle Aged
MH  - Nitric Oxide/metabolism
MH  - Phospholipase C gamma/metabolism
MH  - Phosphorylation
MH  - Platelet Activation/*drug effects
MH  - Platelet Aggregation/drug effects
MH  - Platelet Aggregation Inhibitors/therapeutic use
MH  - Platelet Function Tests
MH  - Protein Kinase C/metabolism
MH  - Protein-Tyrosine Kinases/metabolism
MH  - Retinal Vein Occlusion/*blood/drug therapy/metabolism
MH  - Syk Kinase
MH  - Time Factors
EDAT- 2007/02/01 09:00
MHDA- 2007/03/24 09:00
CRDT- 2007/02/01 09:00
PHST- 2007/02/01 09:00 [pubmed]
PHST- 2007/03/24 09:00 [medline]
PHST- 2007/02/01 09:00 [entrez]
AID - 07020218 [pii]
PST - ppublish
SO  - Thromb Haemost. 2007 Feb;97(2):218-27.